Literature DB >> 9524792

An open, controlled study of two non-absorbable antibiotics for the oral treatment of paediatric infectious diarrhoea.

L Frisari1, V Viggiano, M Pelagalli.   

Abstract

Forty-nine children in need of antibacterial treatment for a severe episode of bacterial diarrhoea were consecutively treated with either an oral paediatric suspension of rifaximin (100 mg every six hours for an average of four days: 24 patients), or paromomycin (125 mg every six hours for an average of four days: 25 patients). Stools (number and form), enteritis symptoms and signs, and intolerance manifestations were all monitored on each day of treatment. A stool culture was performed on the first available stool after enrolment and after the end of treatment to monitor the drugs' antibacterial activity. A similar rate of bacteriological cure, with normalisation of stools and elimination of the clinical symptomatology, was attained by the two antibiotics, with statistical significance of changes vs. baseline being apparent on the second treatment day, in both treatment groups. Rifaximin results were quicker (treatment lasted three days in several cases) and on the whole slightly better (though without statistical significance) than those of paromomycin: 21/24 vs. 20/25 children were completely cured, with a failure rate of three and five cases, respectively. Systemic and local tolerance of both treatments were very good in all children.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9524792     DOI: 10.1185/03007999709113341

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  3 in total

1.  Antimicrobial resistance of diarrheagenic Escherichia coli isolated from children under the age of 5 years from Ifakara, Tanzania.

Authors:  J Vila; M Vargas; C Casals; H Urassa; H Mshinda; D Schellemberg; J Gascon
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

2.  Utility of the Nonabsorbed (<0.4%) Antibiotic Rifaximin in Gastroenterology and Hepatology.

Authors:  Chinyu G Su; Faten Aberra; Gary R Lichtenstein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-03

Review 3.  Safety and tolerability of the antibacterial rifaximin in the treatment of travellers' diarrhoea.

Authors:  Charles D Ericsson
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.